



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC, Phase 4,  
Opp. PCI, Ankleshwar – 393 002,  
Gujarat, India  
Tel : (02646) 220774  
Fax : (02646) 251291  
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India.  
Tel : (91-22) 26701050/1/2  
Fax : (91-22) 26701053  
E: contact@samratpharmachem.in

30 July, 2019

To,  
Department of Corporate Services,  
BSE Limited  
25th Floor, P J Towers,  
Dalal Street,  
Mumbai - 400 001.

Dear Sir,

### Sub: Reconciliation of Share Capital Audit f.t.q.e. 30/06/2019

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are forwarding herewith a Certificate issued by Practicing Company Secretary after conducting Reconciliation of Share Capital Audit for the quarter ended June 30, 2019.

Thanking you,

Yours faithfully,  
For Samrat Pharmachem Limited

Sandeep Prajapati  
Compliance Officer



**Aqueel A. Mulla**

B.Com., L.L.M., F.C.S., A.C.I.S. (U.K.), D.I.T.

**A. A. MULLA & ASSOCIATES**  
**Company Secretaries**

---

3<sup>rd</sup> Floor, New Hari Leela House, 34/38, Mint Road, Opp. G.P.O., Mumbai – 400 001.  
Tel: 022-22644435 Fax: 022-22644434 M: 9892237418 Email: aqueelmulla@gmail.com

**30 July, 2019**

**The Board of Directors,  
M/s. Samrat Pharmachem Limited**


Plot No. A2/3445,  
GIDC, Phase 4,  
Ankleshwar – 393 002,  
Gujarat.

Dear Sir,

Pursuance to Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018, we are enclosing herewith a Certificate issued by us after conducting Reconciliation of Share Capital Audit for the quarter ended **30<sup>th</sup> June, 2019**, as required under the said circular.

Please find the same in order & forward a copy of the same to the respective stock exchanges.

Yours faithfully,  
**For A.A. Mulla & Associates**  
**Company Secretaries**

  
**Aqueel A. Mulla**  
Proprietor



## Reconciliation of Share Capital Audit Report

(As per Regulation 76 of the SEBI (Depositories & Participants) Regulation 2018).

Sr. No	Particulars	Details	
1.	<b>For Quarter Ended</b>	<b>30<sup>th</sup> June, 2019</b>	
2.	<b>ISIN</b>	<b>INE103E01016</b>	
3.	Face Value	Rs. 10	
4.	Name of the Company	Samrat Pharmachem Limited	
5.	Registered Office Address	Plot No. A2/3445, GIDC, Phase 4, Ankleshwar – 393 002, Gujarat.	
6.	Correspondence Address	701/702, Business Square, M. A. Road, Andheri (West), Mumbai – 400 058.	
7.	Tel No. & Fax No.	Tel : (022) 26701050 Fax : (022) 26701053	
8.	Email Address Website	contact@samratpharmachem.in www.samratpharmachem.com	
9.	Names of the stock exchanges where the company's securities are listed.	Mumbai	
10.	Issued Capital	No. of shares	% of total issued capital
		30,89,700	100.00 %
11.	Listed Capital (Exchange Wise) As per company records ▪ It is same for all the exchanges	30,89,700	100.00 %
12.	Held in dematerialized form in CDSL	3,88,036	12.56 %
13.	Held in dematerialized form in NSDL	23,25,054	75.25 %
14.	Physical	3,76,610	12.19 %
15.	Total No. of shares (12+13+14)	30,89,700	100.00 %
16.	Reasons for difference if any, between (10&11), (10&15), (11&15)	Nil	

17. Certifying the details of changes in share capital during the quarter under consideration as per table below:

Particulars ***	No. of shares	Applied / Not applied for listing	Listed on stock exchanges (specify names)	Whether intimated to CDSL	Whether intimated to NSDL	In-prin. Appr. Pending for SE (Specify Names)
Nil	Nil	Nil	Nil	Nil	Nil	Nil

\*\*\* Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify)

18.	Registrar of members is updated (Yes/No)	Yes
	If not, updated upto which date	Not Applicable



19. Reference of previous quarter with regards to excess de-materialised shares, if any.


20. Has the Company resolved the matter mentioned in Point No. 19 above in the current quarter? If not, reason why?

21. Mention the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending beyond 21 days with the reasons for delay :

Total No. of demat requests	No. of requests	No. of shares	Reason for delay
Confirmed after 21 days	0	0	-
Pending for more than 21 days	0	0	-

22.	Name, Tel No., Fax No. & Membership No. of the Compliance Officer of the Co.	Name : Mr. Sandeep Umashankar Prajapti Tel No. : (91) 9867228874 Fax No. : - Membership : ACS-57823 No. Email : contact@samratpharmachem.in
-----	--	--

23.	Name, Address, Tel No. & Fax No., Regn No. of the Certifying CA/CS	Name : A. A. Mulla & Associates Company Secretaries Address : 3 <sup>rd</sup> Floor, New Hari Leela House, 34/38, Mint Road, Opp. G.P.O., Mumbai – 400 072. Tel No. : (022) 22644435 Fax No. : (022) 22644434 Cell No. : 9892237418 Email : aqueelmulla@gmail.com
-----	--	---

24.	Appointment of common agency for share registry work	Name : Link Intime India Pvt Ltd Address : C-101, 247 Park, L. B. S. Marg, Vikhroli (West), Mumbai – 400 083, Maharashtra. Tel No. : (022) 49186000 Fax No. : (022) 49186060 Email : rnt.helpdesk@linkintime.co.in Kind Attn : Ms. Shweta Poojari
-----	--	--

25. Any other detail that the CA/CS may like to provide (eg BIFR Company, de-listing from SE, etc)

**Non- Compliance with Regulation 6(1) of SEBI (LODR) Regulation, 2015 for the Quarter ended March 2019.**


BSE Letter Dt. 14-05-2019 LIST/COMP/530125/Reg. 6(1) – Mar-19/50/2019-20 imposing a penalty of Rs. 69,620 for non-compliance with requirement to appoint a qualified company secretary as the compliance officer.



Date : 30 July, 2019  
Place : Mumbai



For A. A. Mulla & Associates  
Company Secretaries

  
Aqueel A Mulla  
Proprietor  
C.P. No. 3237  
CS No. 2973